Project Grant R01HL176565
Award Date 8/27/25
Completion Date 5/31/29
Dollars Obligated $512K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The Research Institute at Nationwide Children's Hospital was awarded a $711,039 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to investigate the role of cardiac m6A methyltransferases in the pathogenesis of early-onset dilated cardiomyopathy (DCM) in fetuses. The project aims to determine the functions of the methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their dysregulation contributes to fetal...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $167,400 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dr. Joshua Meisner at the University of Michigan. The award aims to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by truncating variants of the MYBPC3 gene, a leading cause of sudden cardiac death and heart failure, especially in children and adolescents....
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $811,885 in funding to the J. David Gladstone Institutes in San Francisco, California. The award supports research to investigate the epigenomic mechanisms governing cardiac fibrosis and heart failure pathogenesis. Key goals include understanding the role of the MEOX1 transcriptional regulator in fibroblast activation and fibrosis, with...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $694,754 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Washington University in Missouri. The 5-year grant, which commenced on August 1, 2025, will support research to investigate the fundamental molecular mechanisms driving the pathogenesis of key troponin cardiomyopathy mutations and their effects on cellular and tissue function. The...
- This $149,804 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the structural and functional features of the native cardiac sarcomere in hypertrophic cardiomyopathy (HCM). The project aims to directly observe the conformational changes in the beta-myosin motor protein caused by HCM-inducing mutations and the FDA-approved drug mavacamten, using advanced cryo-electron tomography...
- This $683,048 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research by the Research Institute at Nationwide Children's Hospital to investigate the pathogenesis of left ventricular noncompaction cardiomyopathy (LVNC), a rare genetic heart condition. The research aims to elucidate the cellular and molecular mechanisms through which the zinc ion importer ZIP8 impacts myocardial trabeculation and compaction...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research, aims to ameliorate cardiac fibrosis using diverse human cardiac organoid models. The $159,512 award will support research to discover and validate compounds that can combat the activation of cardiac fibroblasts, a key driver of cardiac fibrosis in dilated cardiomyopathy (DCM). The project will utilize 3D induced pluripotent stem cell-derived cardiac...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $194,375 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Santa Barbara (UCSB) to study the impact of cardiomyopathy-driven extracellular matrix (ECM) remodeling on myocardial viscoelasticity and its effects on cardiomyocyte phenotype. The 24-month project aims to: 1) Determine how cardiomyopathy alters myocardial viscoelasticity, and 2) Assess how matrix viscoelasticity regulates...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $739,236 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Cincinnati Children's Hospital Medical Center to support research on the cellular mechanisms underlying resistance to mTOR inhibitor drugs in lymphangioleiomyomatosis (LAM), a rare and destructive lung disease. The research aims to elucidate how the activation of YAP-Wnt signaling pathways promotes a "LAM cell stemness state" that...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...